NL-OMON35304CompletedNot Applicable
A single-center, open-label study of excretion balance, pharmacokinetics, and metabolism of 14carbon-labeled UCB0942 after 100 mg single oral dose administration in healthy male subjects - [14C]-UCB0942 ADME study
CB Celltech0 sites6 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •- healthy male subjects
- •- 18-55 yrs, inclusive
- •- BMI:18-30 kg/m2, inclusive, and weighs at least 50 kg
- •- non-smoker
Exclusion Criteria
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Investigators
Similar Trials
Completed
Not Applicable
A study to develop a method to analyse the uptake and degradation of a spice and flavouring agent known as eugenolThis study involves healthy adult never smokers to obtain information on biomarkers of exposure to eugenol in urineISRCTN67240844British American Tobacco (Investments) Ltd. (UK)5
Active, not recruiting
Phase 1
The effect of 20 mg ambroxol on artificially induced coughacute cough assouciated with URTIMedDRA version: 20.0 Level: LLT Classification code 10066522 Term: Acute cough System Organ Class: 100000004855EUCTR2017-003980-36-GBHull and East Yorkshire Hospitals NHS Trust14
Completed
Not Applicable
Single center, open-label study investigating the excretion balance, pharmacokinetics and metabolism of a single oral dose of [14C]-labeled RO6889450 in healthy male volunteers10039628SchizophreniaNL-OMON51079F. Hoffman-La Roche Ltd6
Recruiting
Phase 4
An open-label, single-center, exploratory study of the safety and efficacy of avalglucosidase alfa in patients with non-classic Pompe disease aged >= 5 years.glycogen storage disease type II or acid maltase deficiency10027424Pompe diseaseNL-OMON56788Erasmus MC, Universitair Medisch Centrum Rotterdam6
Active, not recruiting
Not Applicable
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDEEUCTR2009-016457-18-GRAstellas Pharma Europe Ltd300